Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1834993
Max Phase: Preclinical
Molecular Formula: C28H30ClN5O7S
Molecular Weight: 616.10
Molecule Type: Small molecule
Associated Items:
ID: ALA1834993
Max Phase: Preclinical
Molecular Formula: C28H30ClN5O7S
Molecular Weight: 616.10
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CN(C)CCOc1ccc2[nH]c(C(=O)N3CC(CCl)c4c3cc([N+](=O)[O-])c3cc(S(=O)(=O)NCCO)ccc43)cc2c1
Standard InChI: InChI=1S/C28H30ClN5O7S/c1-32(2)8-10-41-19-3-6-23-17(11-19)12-24(31-23)28(36)33-16-18(15-29)27-21-5-4-20(42(39,40)30-7-9-35)13-22(21)25(34(37)38)14-26(27)33/h3-6,11-14,18,30-31,35H,7-10,15-16H2,1-2H3
Standard InChI Key: KRUNPKDABQVLHA-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 616.10 | Molecular Weight (Monoisotopic): 615.1554 | AlogP: 3.42 | #Rotatable Bonds: 11 |
Polar Surface Area: 158.11 | Molecular Species: BASE | HBA: 8 | HBD: 3 |
#RO5 Violations: 1 | HBA (Lipinski): 12 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 9.99 | CX Basic pKa: 8.72 | CX LogP: 2.01 | CX LogD: 0.88 |
Aromatic Rings: 4 | Heavy Atoms: 42 | QED Weighted: 0.13 | Np Likeness Score: -1.17 |
1. Stevenson RJ, Denny WA, Ashoorzadeh A, Pruijn FB, van Leeuwen WF, Tercel M.. (2011) The effect of a bromide leaving group on the properties of nitro analogs of the duocarmycins as hypoxia-activated prodrugs and phosphate pre-prodrugs for antitumor therapy., 19 (20): [PMID:21920763] [10.1016/j.bmc.2011.08.045] |
2. Stevenson RJ, Denny WA, Tercel M, Pruijn FB, Ashoorzadeh A.. (2012) Nitro seco analogues of the duocarmycins containing sulfonate leaving groups as hypoxia-activated prodrugs for cancer therapy., 55 (6): [PMID:22339090] [10.1021/jm201717y] |
3. Tercel M, Lee HH, Mehta SY, Youte Tendoung JJ, Bai SY, Liyanage HDS, Pruijn FB.. (2017) Influence of a Basic Side Chain on the Properties of Hypoxia-Selective Nitro Analogues of the Duocarmycins: Demonstration of Substantial Anticancer Activity in Combination with Irradiation or Chemotherapy., 60 (13): [PMID:28644035] [10.1021/acs.jmedchem.7b00563] |
Source(1):